Christopher Williams
Christopher Williams has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Mairin A. Jerome
Physical Medicine and Rehabilitation, Regenerative SportsCare Institute, New York, USA
2 shared publications - Adam Street
Department of Orthopedics and Sports Medicine, Emory University, Atlanta, USA
1 shared publication - Brendan Martin
Department of Physical Medicine and Rehabilitation, University of California, Irvine, CA 92697, USA
1 shared publication - Chaz Fausel
Physical Medicine and Rehabilitation, Advanced Regenerative Health, Denver, USA
1 shared publication - Christopher J. Centeno
Centeno-Schultz Clinic, Broomfield, CO 80021, USA
1 shared publication Cleo Stafford
Physical Medicine and Rehabilitation, Emory University School of Medicine, Atlanta, USA
1 shared publication
Latest Publications
- Open Access
- 23 October 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (11) , 2433
Platelet Dose, Concentration, and Injectate Volume in Platelet-Rich Plasma Therapy: An Evidence-Informed Review of Large-Joint Osteoarthritis
Background/Objectives: Platelet-rich plasma (PRP) preparations vary widely, and most studies report concentration rather than absolute platelet dose, limiting cross-study comparison. This review provides an evidence-informed synthesis of platelet dose, concentration, and injectate volume in knee, hip, and glenohumeral osteoarthritis (OA). Methods: A PubMed-based narrative review included 26 primary studies (16 knee, nine hip, and one glenohumeral); systematic reviews provided context. Dose was classified as directly reported, calculated from measured product characteristics, nominally estimated, or assumption-dependent/unverifiable. Assumption-dependent values were excluded from numerical ranges. Randomized trials were assessed with the Cochrane Risk of Bias 2 tool. Results: Knee OA provided the strongest dose-related evidence. Reported, calculated, or aggregate study-level dose estimates ranged from approximately 2.5 to 13.7 billion platelets per injection, with findings suggesting a dose-related signal at approximately 5 billion platelets or greater. In hip OA, measured protocols associated with clinical improvement delivered approximately 6.2–7.0 billion platelets per injection. Glenohumeral evidence was limited to one trial. However, overall, the available evidence did not establish validated minimum or optimal dose thresholds. Conclusions: In knee OA, the available literature shows a dose-related signal at approximately 5 billion platelets or greater per injection, while hip studies report measured protocols around 6–7 billion platelets per injection. These findings are descriptive rather than prescriptive and do not establish clinical dosing thresholds or recommendations. Glenohumeral evidence remains insufficient for dose-specific conclusions.
- 23 October 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (11) , 2433
Open AccessPlatelet Dose, Concentration, and Injectate Volume in Platelet-Rich Plasma Therapy: An Evidence-Informed Review of Large-Joint Osteoarthritis
Background/Objectives: Platelet-rich plasma (PRP) preparations vary widely, and most studies report concentration rather than absolute platelet dose, limiting cross-study comparison. This review provides an evidence-informed synthesis of platelet dose, concentration, and injectate volume in knee, hip, and glenohumeral osteoarthritis (OA). Methods: A PubMed-based narrative review included 26 primary studies (16 knee, nine hip, and one glenohumeral); systematic reviews provided context. Dose was classified as directly reported, calculated from measured product characteristics, nominally estimated, or assumption-dependent/unverifiable. Assumption-dependent values were excluded from numerical ranges. Randomized trials were assessed with the Cochrane Risk of Bias 2 tool. Results: Knee OA provided the strongest dose-related evidence. Reported, calculated, or aggregate study-level dose estimates ranged from approximately 2.5 to 13.7 billion platelets per injection, with findings suggesting a dose-related signal at approximately 5 billion platelets or greater. In hip OA, measured protocols associated with clinical improvement delivered approximately 6.2–7.0 billion platelets per injection. Glenohumeral evidence was limited to one trial. However, overall, the available evidence did not establish validated minimum or optimal dose thresholds. Conclusions: In knee OA, the available literature shows a dose-related signal at approximately 5 billion platelets or greater per injection, while hip studies report measured protocols around 6–7 billion platelets per injection. These findings are descriptive rather than prescriptive and do not establish clinical dosing thresholds or recommendations. Glenohumeral evidence remains insufficient for dose-specific conclusions.
- Open Access
- 27 February 2025
- Published by Springer Nature in Cureus
- Vol. 17 (2) , e79791
Ulnar Neuropathy Hydrodissection With Platelet Lysate and Prolotherapy: A Case Series and Review of the Literature
This case series highlights both pain and function outcomes of three patients who underwent hydrodissection of the ulnar nerve with platelet lysate and prolotherapy for symptomatic ulnar nerve entrapment of the elbow. All patients reported significant long-term symptom improvement, which reached more than 75% regarding pain and function and greater than 80% Single Assessment Numeric Evaluation (SANE) evaluation at the follow-up. The outcomes of this case series suggest that hydrodissection with platelet lysate and dextrose neuroprolotherapy may provide an alternative viable non-surgical treatment option for patients with ulnar neuropathy.
- 27 February 2025
- Published by Springer Nature in Cureus
- Vol. 17 (2) , e79791
Open AccessUlnar Neuropathy Hydrodissection With Platelet Lysate and Prolotherapy: A Case Series and Review of the Literature
This case series highlights both pain and function outcomes of three patients who underwent hydrodissection of the ulnar nerve with platelet lysate and prolotherapy for symptomatic ulnar nerve entrapment of the elbow. All patients reported significant long-term symptom improvement, which reached more than 75% regarding pain and function and greater than 80% Single Assessment Numeric Evaluation (SANE) evaluation at the follow-up. The outcomes of this case series suggest that hydrodissection with platelet lysate and dextrose neuroprolotherapy may provide an alternative viable non-surgical treatment option for patients with ulnar neuropathy.
- Open Access
- 19 February 2023
- Published by Springer Nature in Cureus
- Vol. 15 (2) , e35189
Traumatic Humeral Shaft Non-union With Ulnar Nerve Transection: An Orthobiologics Success Story
Long bone non-union is a detrimental, yet common condition that affects many individuals after injury. It can lead to significant pain and weakness that may impact lifetime productivity and quality of life. This report describes a patient who suffered from greater than two years of a distal humerus fracture non-union along with an ulnar nerve transection that failed traditional surgical management and underwent a percutaneous injection with bone marrow aspirate concentrate, platelet-rich plasma, and platelet lysate, demonstrating subsequent fracture resolution and strength improvement.
- 19 February 2023
- Published by Springer Nature in Cureus
- Vol. 15 (2) , e35189
Open AccessTraumatic Humeral Shaft Non-union With Ulnar Nerve Transection: An Orthobiologics Success Story
Long bone non-union is a detrimental, yet common condition that affects many individuals after injury. It can lead to significant pain and weakness that may impact lifetime productivity and quality of life. This report describes a patient who suffered from greater than two years of a distal humerus fracture non-union along with an ulnar nerve transection that failed traditional surgical management and underwent a percutaneous injection with bone marrow aspirate concentrate, platelet-rich plasma, and platelet lysate, demonstrating subsequent fracture resolution and strength improvement.
- Open Access
- 8 October 2021
- Published by Springer Nature in Cureus
- Vol. 13 (10)
Regenerative Injection Treatments Utilizing Platelet Products and Prolotherapy for Cervical Spine Pain: A Functional Spinal Unit Approach
The increasing burden of musculoskeletal disorders combined with the high utilization of opiates and the relatively limited ability of traditional approaches to satisfactorily address many of these conditions has spurred an increased interest in alternative treatments such as regenerative medicine therapies. Evidence is growing to support the use of regenerative injection treatments, including prolotherapy, platelet-rich plasma (PRP), platelet lysate (PL), and mesenchymal stromal cells. This study aims to offer a proof of concept via a case series of patients with neck pain treated using a functional spinal unit (FSU) model with combination prolotherapy, PRP, and PL injections. A chart review identified patients with neck pain treated with a combination of cervical injections using concentrated platelets and prolotherapy. A total of 14 patients met the inclusion criteria. The average decrease in the Numeric Pain Score was 2.8 (p = 0.002). The mean decrease in the Functional Rating Index was 27.3 (p = 0.004) at 24 months. Two patients had mild adverse reactions. This case series demonstrates basic safety and clinically significant improvements in patients treated for neck pain with autologous concentrated platelet products and prolotherapy utilizing an FSU treatment protocol. Additional clinical studies are warranted with a larger patient sample size and longer follow-up periods.
- 8 October 2021
- Published by Springer Nature in Cureus
- Vol. 13 (10)
Open AccessRegenerative Injection Treatments Utilizing Platelet Products and Prolotherapy for Cervical Spine Pain: A Functional Spinal Unit Approach
The increasing burden of musculoskeletal disorders combined with the high utilization of opiates and the relatively limited ability of traditional approaches to satisfactorily address many of these conditions has spurred an increased interest in alternative treatments such as regenerative medicine therapies. Evidence is growing to support the use of regenerative injection treatments, including prolotherapy, platelet-rich plasma (PRP), platelet lysate (PL), and mesenchymal stromal cells. This study aims to offer a proof of concept via a case series of patients with neck pain treated using a functional spinal unit (FSU) model with combination prolotherapy, PRP, and PL injections. A chart review identified patients with neck pain treated with a combination of cervical injections using concentrated platelets and prolotherapy. A total of 14 patients met the inclusion criteria. The average decrease in the Numeric Pain Score was 2.8 (p = 0.002). The mean decrease in the Functional Rating Index was 27.3 (p = 0.004) at 24 months. Two patients had mild adverse reactions. This case series demonstrates basic safety and clinically significant improvements in patients treated for neck pain with autologous concentrated platelet products and prolotherapy utilizing an FSU treatment protocol. Additional clinical studies are warranted with a larger patient sample size and longer follow-up periods.
- Open Access
- 27 July 2021
- Published by Springer Nature in Cureus
- Vol. 13 (7) , e16677
Atraumatic Medullary Osteonecrosis of the Tibia and Femur Treated With Intraosseous Orthobiologics
Osteonecrosis (ON) is a painful condition involving bony cell death with resultant architectural collapse. This report discusses the case of a SO-year-old Caucasian female who presented to an outpatient musculoskeletal clinic with severe chronic left knee pain. She had a history of ulcerative colitis and resultant chronic corticosteroid exposure with subsequent development of knee ON. She was treated with an intraosseous autologous bone marrow concentrate (BMC), demineralized bone matrix (DBM), and platelet-rich plasma (PRP) injection. At 11 months post-injection, she demonstrated a significant improvement in pain scores, mobility, activity, and decreased narcotic use. Intraosseous orthobiologic injection for the treatment of knee ON is a promising procedure with a reasonable safety profile that warrants further study as an alternative to surgical intervention.
- 27 July 2021
- Published by Springer Nature in Cureus
- Vol. 13 (7) , e16677
Open AccessAtraumatic Medullary Osteonecrosis of the Tibia and Femur Treated With Intraosseous Orthobiologics
Osteonecrosis (ON) is a painful condition involving bony cell death with resultant architectural collapse. This report discusses the case of a SO-year-old Caucasian female who presented to an outpatient musculoskeletal clinic with severe chronic left knee pain. She had a history of ulcerative colitis and resultant chronic corticosteroid exposure with subsequent development of knee ON. She was treated with an intraosseous autologous bone marrow concentrate (BMC), demineralized bone matrix (DBM), and platelet-rich plasma (PRP) injection. At 11 months post-injection, she demonstrated a significant improvement in pain scores, mobility, activity, and decreased narcotic use. Intraosseous orthobiologic injection for the treatment of knee ON is a promising procedure with a reasonable safety profile that warrants further study as an alternative to surgical intervention.